The B6CaP cells we used to demonstrate the efficacy of 5-FU/p50-IMC against murine prostate cancer were obtained from a cancer that developed after FVB/N strain Hi-Myc mice were crossed onto the B6 background [24]. This evidence concerns the gene MYC and prostate carcinoma.